Salarius Pharmaceuticals, Inc.
SLRX
$0.8768
-$0.0005-0.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.57M | -5.58M | -4.99M | -6.46M | -8.92M |
| Total Depreciation and Amortization | 4.40K | 4.40K | 4.40K | 8.90K | 9.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 229.70K | 273.70K | 308.10K | 490.80K | 529.10K |
| Change in Net Operating Assets | 982.80K | 772.30K | -612.90K | -1.72M | -2.65M |
| Cash from Operations | -4.35M | -4.53M | -5.29M | -7.69M | -11.03M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -403.40K | -466.60K | -529.00K | -570.60K | -453.70K |
| Issuance of Common Stock | 2.18M | 1.53M | 1.53M | 88.70K | 6.68M |
| Repurchase of Common Stock | -- | -- | 0.00 | -100.40K | -100.40K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.78M | 1.06M | 997.50K | -582.20K | 6.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.57M | -3.47M | -4.30M | -8.27M | -4.90M |